The Global Telmisartan Market, by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke,), by Composition (Single and Combinational), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), was valued at US$ 3,880.9 million in 2017, and is projected to exhibit a CAGR of 1.4% over the forecast period (2018 - 2026).
Telmisartan is a prescription medication often prescribed to relax and widen blood vessels in persons with high blood pressure. Telmisartan belongs to a group of drugs called angiotensin II receptor blockers (ARBs). Telmisartan may be used alone or in combination with other medications such as hydrochlorothiazide for treatment of high blood pressure. Increasing awareness regarding hypertension and its management by organizing global campaigns are expected to drive growth of the market. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) participated in global campaigns named May Measurement Month and World Hypertension Day for creating awareness among population related to blood pressure and their management.
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on ”Global Telmisartan Market" by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke), by Composition (Single and Combinational), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Forecast to 2026"
To know the latest trends and insights related to Telmisartan market, click the link below:
Key players are focused on development and launch of new generic product to maximize access to end users for their product in less cost, in turn gaining market share in telmisartan market. For instance, in June 2017, Solco Healthcare, announced its FDA approval for Telmisartan tablets, 20mg, 40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths. Moreover, increasing government initiatives for hypertension management is expected to drive growth of the global Telmisartan market. For instance, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) launched, the India Hypertension Management Initiative (IHMI). The IHMI aims to reduce disability and death related to cardiovascular disease (CVD), by improving control over high blood pressure (hypertension), reducing salt consumption from food, and eliminating artificial trans-fats, which are leading risk factors for developing CVD.
Key Takeaways of the Telmisartan Market: